Drubay Damien, Collette Laurence, Paoletti Xavier
INSERM U1018, CESP, Université Paris-Saclay, UVSQ, Villejuif, F-94805, France.
Gustave Roussy, Service de Biostatistique et D'Epidémiologie, Villejuif, F-94805, France.
Contemp Clin Trials Commun. 2020 Jan 25;17:100529. doi: 10.1016/j.conctc.2020.100529. eCollection 2020 Mar.
Data generated by phase I trials is richer than the classical binary DLT measured at the first cycle used as primary endpoints. Several works developed designs for more informative endpoints, e.g. ordinal toxicity grades and/or longitudinal data which relied however on strong assumptions, in particular the proportional odds (PO) assumption.
We evaluated this PO assumption for the dose and cycle on a large database of individual patient data from 54 phase I clinical trials of molecularly targeted agents. The PO model is a specific case of the continuation ratio logit model (CRLM) with null parameters. We compared the PO and CRLM models using the widely applicable information criterion (WAIC). We considered a longitudinal multivariate ordinal toxicity outcome (cutaneous, digestive, hematological, general disorders, and other toxicities).
WAIC suggested that the CRLM model (WAIC = 30911.58) outperformed the PO model (WAIC = 31432.10). Deviance from PO assumption for dose was observed for digestive and general disorder toxicities. There was moderate cycle effect with slight deviance from PO assumption for the other type of toxicity.
Designs based on PO for dose should be a useful tool for drug with low expected digestive or general disorder toxicity dose-related incidence.
I期试验产生的数据比用作主要终点的首个周期所测量的经典二元剂量限制性毒性(DLT)更丰富。有几项研究针对更具信息量的终点开发了设计方法,例如序贯毒性等级和/或纵向数据,然而这些方法依赖于很强的假设,尤其是比例优势(PO)假设。
我们在一个来自54项分子靶向药物I期临床试验的个体患者数据大数据库上,评估了剂量和周期方面的这一PO假设。PO模型是具有零参数的连续比例logit模型(CRLM)的一个特殊情况。我们使用广泛适用信息准则(WAIC)比较了PO模型和CRLM模型。我们考虑了一个纵向多变量序贯毒性结局(皮肤毒性、消化系统毒性、血液学毒性、全身紊乱及其他毒性)。
WAIC表明CRLM模型(WAIC = 30911.58)优于PO模型(WAIC = 31432.10)。在消化系统毒性和全身紊乱毒性方面观察到了与剂量的PO假设的偏差。存在中度的周期效应,在其他类型毒性方面与PO假设略有偏差。
对于预期消化系统或全身紊乱毒性与剂量相关发生率较低的药物,基于PO的剂量设计应是一种有用的工具。